AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 151 min read$NRIX

Hansen Gwenn sold $36K of NRIX

Hansen Gwenn (Chief Scientific Officer) sold 1,452 shares of Nurix Therapeutics, Inc. (NRIX) at $25.00 on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hansen Gwenn
Published Oct 15, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
high confidence
Mentioned
$NRIX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The sale is small and pre‑arranged, so market impact is expected to be negligible.

02

Market read

A routine insider sale with limited materiality; unlikely to affect trading decisions.

03

What to watch

The 10b5‑1 plan may be routine and pre‑scheduled, reducing any informational edge.

Relevance 2/10Novelty 2/10Timing: same day filing

Background

Form 4 filings disclose insider transactions; they are primary sources for regulatory disclosures.

Company-level read

Ticker impact

$NRIXNeutralHigh confidence
Context

Chief Scientific Officer Hansen Gwenn sold 1,452 shares of Nurix Therapeutics for $36,300 on 2026-10-15 via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A 10b5‑1 sale by a senior officer signals personal liquidity need but the amount ($36K) is trivial relative to market cap.

Market effects

Sector

Minimal; biotech sector not materially affected by a small insider sale.

Regional

None; the filing is U.S. SEC‑based and does not affect regional markets.

Global

None; the transaction is company‑specific and low‑scale.

Counterpoint

What could challenge this read

If the insider had insider knowledge, the sale could hint at upcoming negative news, warranting a short‑term watch.

Key entities

  • company
    Nurix Therapeutics, Inc.

    Biotech firm developing targeted protein degradation therapies.

  • person
    Hansen Gwenn

    Chief Scientific Officer of Nurix Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

OCT 13
$NRIXMedAI 8/10

Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, driven by Roche license revenue. Net income was $549.8M, a $636.2M swing from a loss last year. Diluted EPS was $4.73. The company advanced clinical trials and expanded partnerships with Roche, Gilead, Sanofi, and Pfizer, receiving $1.2B to date with up to $7.2B in potential milestones and royalties.

tradingview.com2 min
OCT 13
$NRIXHighAI 8/10

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobruti

SEC EDGAR 8-K2 min